On point estimation of the abnormality of a Mahalanobis index

Mahalanobis distance may be used as a measure of the disparity between an individual’s profile of scores and the average profile of a population of controls. The degree to which the individual’s profile is unusual can then be equated to the proportion of the population who would have a larger Mahalanobis distance than the individual. Several estimators of this proportion are examined. These include plug-in maximum likelihood estimators, medians, the posterior mean from a Bayesian probability matching prior, an estimator derived from a Taylor expansion, and two forms of polynomial approximation, one based on Bernstein polynomial and one on a quadrature method. Simulations show that some estimators, including the commonly-used plug-in maximum likelihood estimators, can have substantial bias for small or moderate sample sizes. The polynomial approximations yield estimators that have low bias, with the quadrature method marginally to be preferred over Bernstein polynomials. However, the polynomial estimators sometimes yield infeasible estimates that are outside the 0–1 range. While none of the estimators are perfectly unbiased, the median estimators match their definition; in simulations their estimates of the proportion have a median error close to zero. The standard median estimator can give unrealistically small estimates (including 0) and an adjustment is proposed that ensures estimates are always credible. This latter estimator has much to recommend it when unbiasedness is not of paramount importance, while the quadrature method is recommended when bias is the dominant issue

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders.

Many studies have reported that heavy substance use is associated with impaired response inhibition. Studies typically focused on associations with a single substance, while polysubstance use is common. Further, most studies compared heavy users with light/non-users, though substance use occurs along a continuum. The current mega-analysis accounted for these issues by aggregating individual data from 43 studies (3610 adult participants) that used the Go/No-Go (GNG) or Stop-signal task (SST) to assess inhibition among mostly "recreational" substance users (i.e., the rate of substance use disorders was low). Main and interaction effects of substance use, demographics, and task-characteristics were entered in a linear mixed model. Contrary to many studies and reviews in the field, we found that only lifetime cannabis use was associated with impaired response inhibition in the SST. An interaction effect was also observed: the relationship between tobacco use and response inhibition (in the SST) differed between cannabis users and non-users, with a negative association between tobacco use and inhibition in the cannabis non-users. In addition, participants' age, education level, and some task characteristics influenced inhibition outcomes. Overall, we found limited support for impaired inhibition among substance users when controlling for demographics and task-characteristics

Optimal measurement conditions for EEG/MEG source analysis

Electromagnetic source analysis yields estimates of the sources of the Electro- and/or MagnetoEncephaloGram (EEG/MEG) and thus generates a functional description of the human brain. The standard errors of the source estimates are influenced by the number and position of EEG/MEG is measured. Therefore, optimal design theory is applied to determine the required number and position of sensors, the required number of samples, and the required number of trials. To that end, the Fedorov exchange algorithm is extended to incorporate multi-response models. A simulation study and an empirical study on visual evoked potentials indicate that the proposed method is fast and reliable, and improves source precision considerably

Probable Locally Acquired Babesia divergens–Like Infection in Woman, Michigan, USA

We report an asplenic patient who was infected with Babesia divergens–like/MO-1. The clinical course was complicated by multiorgan failure that required intubation and dialysis. The patient recovered after an exchange transfusion and antimicrobial drug therapy. Physicians should be alert for additional cases, particularly in asplenic persons